EMEA-000527-PIP02-10

Key facts

Invented name
Lucentis
Active substance
ranibizumab
Therapeutic area
Ophthalmology
Decision number
P/291/2010
PIP number
EMEA-000527-PIP02-10
Pharmaceutical form(s)
  • Solution for injection – single-use vial
  • Solution for injection – single-use pre-filled syringe
Condition(s) / indication(s)
Treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia
Route(s) of administration
Intravitreal use
Contact for public enquiries
Novartis Europharm Limited

 

paediatric.enquiries@novartis.com
Phone: +41 61 324 1111
Fax: +41 61 324 8001

 

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating